XAV939 inhibits the stemness and migration of neuroblastoma cancer stem cells via repression of tankyrase 1

International Journal of Oncology

Volumn 45, Issue 1, 2014, Pages 121-128

  Tian, Xiaohong ^a   Hou, Weijian ^a   Bai, Shuling ^a   Fan, Jun ^a   Tong, Hao ^a   Xu, He ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Cancer stem cells; Neuroblastoma cell line; Stemness; XAV939

Indexed keywords

ANTINEOPLASTIC AGENT; CD133 ANTIGEN; ENZYME INHIBITOR; ETOPOSIDE; TANKYRASE; UNCLASSIFIED DRUG; XAV 939; 7,8 DIHYDRO 2 [4 (TRIFLUOROMETHYL)PHENYL] 5H THIOPYRANO[4,3 D]PYRIMIDIN 4 OL; FUSED HETEROCYCLIC RINGS; GLYCOPROTEIN; LEUKOCYTE ANTIGEN; PEPTIDE; TNKS PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER STEM CELL; CELL ISOLATION; CELL MIGRATION; CELL POPULATION; DRUG TARGETING; ELECTRON MICROSCOPY; GENE EXPRESSION; GENE REPRESSION; HUMAN; HUMAN CELL; NEUROBLASTOMA; PRIORITY JOURNAL; RNA INTERFERENCE; ANTAGONISTS AND INHIBITORS; CELL MOTION; CYTOLOGY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; TUMOR CELL CULTURE; ULTRASTRUCTURE;

ANTIGENS, CD; CELL MOVEMENT; ENZYME INHIBITORS; ETOPOSIDE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOPROTEINS; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; NEOPLASTIC STEM CELLS; NEUROBLASTOMA; PEPTIDES; TANKYRASES; TUMOR CELLS, CULTURED;

EID: 84902594713     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2406     Document Type: Article

References (48)

1. Hamburger AW and Salmon SE: Primary bioassay of human tumor stem cells. Science 197: 461-463, 1977.
2. Reya T, Morrison SJ, Clarke MF and Weissman IL: Stem cells, cancer, and cancer stem cells. Nature 414: 105-111, 2001.
3. Huntly BJP and Gilliland DG: Leukaemia stem cells and the evolution of cancer-stem-cell research. Nat Rev Cancer 5: 311-321, 2005.
4. Ross RA and Spengler BA: Human neuroblastoma stem cells. Semin Cancer Biol 17: 241-247, 2007.
5. Bilir A, Erguven M, Yazihan N, Aktas E, Oktem G and Sabanci A: Enhancement of vinorelbine-induced cytotoxicity and apoptosis by clomipramine and lithium chloride in human neuroblastoma cancer cell line SH-SY5Y. J Neurooncol 100: 385-395, 2010.
6. Abbott BL: ABCG2 (BCRP): a cytoprotectant in normal and malignant stem cells. Clin Adv Hematol Oncol 4: 63-72, 2006.
7. Nan JN, Hu XG and Li HX: Research progress in tumor stem cells: literature retrieval results based on international database. Chin J Tiss Eng Res 516: 1085-1093, 2012.
8. Huang SM, Mishina YM, Liu S, et al: Tankyrase inhibition stabilizes axin and antagonizes Wnt signaling. Nature 461: 614-620, 2009.
9. Chen B, Dodge ME, Tang W, et al: Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nat Chem Biol 5: 100-107, 2009.
10. Xu D, Zheng C, Bergenbrant S, Holm G, Björkholm M, Yi Q and Gruber A: Telomerase activity in plasma cell dyscrasias. Br J Cancer 84: 621-625, 2001.
11. MacNamara B, Wang W, Chen Z, et al: Telomerase activity in relation to pro- and anti-apoptotic protein expression in high grade non-Hodgkin's lymphomas. Haematologica 86: 386-393, 2001.
12. Klapper W, Krams M, Qian W, Janssen D and Parwaresch R: Telomerase activity in B-cell non-Hodgkin lymphomas is regulated by hTERT transcription and correlated with telomere-binding protein expression but uncoupled from proliferation. Br J Cancer 89: 713-719, 2003.
13. Gelmini S, Poggesi M, Distante V, et al: Tankyrase, a positive regulator of telomere elongation, is over expressed in human breast cancer. Cancer Lett 216: 81-87, 2004.
14. Gelmini S, Poggesi M, Pinzani P, et al: Distribution of tankyrase-1 mRNA expression in colon cancer and its prospective correlation with progression stage. Oncol Rep 16: 1261-1266, 2006.
15. Gelmini S, Quattrone S, Malentacchi F, et al: Tankyrase-1 mRNA expression in bladder cancer and paired urine sediment: preliminary experience. Clin Chem Lab Med 45: 862-866, 2007.
16. Shervington A, Patel R, Lu C, et al: Telomerase subunits expression variation between biopsy samples and cell lines derived from malignant glioma. Brain Res 1134: 45-52, 2007.
17. Tian XH, Hou WJ, Fang Y, et al: XAV939, a tankyrase 1 inhibitior, promotes cell apoptosis in neuroblastoma cell lines by inhibiting Wnt/β-catenin signaling pathway. J Exp Clin Cancer Res 32: 100-109, 2013.
18. Vangipuram SD, Buck SA and Lyman WD: Wnt pathway activity confers chemoresistance to cancer stem-like cells in a neuroblastoma cell line. Tumour Biol 33: 2173-2183, 2012.
19. Al-Hajj M and Clarke MF: Self renewal and solid tumor stem cells. Oncogene 23: 7274-7282, 2004.
20. Dean M, Fojo T and Bates S: Tumour stem cells and drug resistance. Nat Rev Cancer 5: 275-284, 2005.
21. Lou H and Dean M: Targeted therapy for cancer stem cells: the patched pathway and ABC transporters. Oncogene 26: 1357-1360, 2007.
22. Hadnagy A, Gaboury L, Beaulieu R and Balicki D: SP analysis may be used to identify cancer stem cell populations. Exp Cell Res 312: 3701-3710, 2006.
23. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ and Clarke MF: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100: 3983-3988, 2003.
24. Bonnet D and Dick JE: Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3: 730-737, 1997.
25. Collins AT, Berry PA, Hyde C, Stower MJ and Maitland NJ: Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65: 10946-10951, 2005.
26. O'Brien CA, Pollett A, Gallinger S and Dick JE: A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445: 106-110, 2007.
27. Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al: Identification and expansion of human colon-cancer-initiating cells. Nature 445: 111-115, 2007.
28. Singh SK, Clarke ID, Terasaki M, et al: Identification of a cancer stem cell in human brain tumors. Cancer Res 63: 5821-5828, 2003.
29. Singh SK, Hawkins C, Clarke ID, et al: Identification of human brain tumor initiating cells. Nature 432: 396-401, 2004.
30. Mahller YY, Williams JP, Baird WH, et al: Neuroblastoma cell lines contain pluripotent tumor initiating cells that are susceptible to a targeted oncolytic virus. PLoS One 4: e4235, 2009.
31. Hemmati HD, Nakano I, Lazareff JA, et al: Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci USA 100: 15178-15183, 2003.
32. Na YR, Seok SH, Kim DJ, et al: Isolation and characterization of spheroid cells from human malignannt melanoma cell line WM-266-4. Tumor Biol 30: 300-309, 2009.
33. Di Fiore R, Santulli A, Ferrante RD, et al: Identification and expansion of human osteosarcoma-cancer-stem cells by long-term 3-aminobenzamide treatment. J Cell Physiol 219: 301-313, 2009.
34. Das B, Tsuchida R, Malkin D, Koren G, Baruchel S and Yeger H: Hypoxia enhances tumor stemness by increasing the invasive and tumorigenic side population fraction. Stem Cells 26: 1818-1830, 2008.
35. Marzi I, D'Amico M, Biagiotti T, et al: Purging of the neuroblastoma stem cell compartment and tumor regression on exposure to hypoxia or cytotoxic treatment. Cancer Res 67: 2402-2407, 2007.
36. Deng YW, Fang JS, Li MC, et al: Correlation research between cancer stem cells and the pathological grades of neuroepithelial tumors. J Cent South Uniu (Med Sci) 31: 45-51, 2006.
37. Abbott A: Cancer: the root of the problem. Nature 442: 742-743, 2006.
38. Lindvall C, Bu W, Williams BO and Li Y: Wnt signaling, stem cells, and the cellular origin of breast cancer. Stem Cell Rev 3: 157-168, 2007.
39. Fu JK, Wang Z and Wei S: Alterations and its mechanisms of Wnt signal pathway in human high-matastatatic large cell lung cancer cell line L9981 by transfecting with Nm23-H1 gene. Chin J Lung Cancer 12: 477-479, 2009.
40. Nguyen DX, Chiang AC, Zhang XH, et al: WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis. Cell 138: 51-62, 2009.
41. Akiri G, Cherian MM, Vijayakumar S, Liu G, Bafico A and Aaronson SA: Wnt pathway aberrations including autocrine Wnt activation occur at high frequency in human non-small-cell lung carcinoma. Oncogene 28: 2163-2172, 2009.
42. Sun JZ, Yang XX, Hu NY, Li X, Li FX and Li M: Genetic variants in MMP9 and TGF2 contribute to susceptibility to lung cancer. Chin J Cancer 23: 183-187, 2011.
43. Kim J, You L, Xu Z, et al: Wnt inhibitory factor inhibits lung cancer cell growth. J Thorac Cardiovasc Surg 133: 733-737, 2007.
44. Katoh Y and Katoh M: Comparative genomics on PROM1 gene encoding stem cell marker CD133. Int J Mol Med 19: 967-970, 2007.
45. Horst D, Kriegl L, Engel J, Jung A and Kirchner T: CD133 and nuclear beta-catenin: the marker combination to detect high risk cases of low stage colorectal cancer. Eur J Cancer 45: 2034-2040, 2009.
46. Ruck P, Xiao JC, Pietsch T, Von Schweinitz D and Kaiserling E: Hepatic stem-like cells in hepatoblastoma: expression of cytokeratin 7, albumin and oval cell associated antigens detected by OV-1 and OV-6. Histopathology 31: 324-329, 1997.
47. Karner CM, Merkel CE, Dodge M, Ma Z, Lu J, Chen C, Lum L and Carroll TJ: Tankyrase is necessary for canonical Wnt signaling during kidney development. Dev Dyn 239: 2014-2023, 2010.
48. Chung SS, Giehl N, Wu Y and Vadgama JV: STAT3 activation in HER2-overexpressing breast cancer promotes epithelial-mesenchymal transition and cancer stem cell traits. Int J Oncol 44: 403-411, 2014.